By Professor Richard Bryan Lock

Journal articles

Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 62, pp. 1106 - 1109, http://dx.doi.org/10.1002/pbc.25329

Tursky ML; Beck D; Thoms JAI; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JWH; Olivier J; Lock RB; MacKenzie KL; Pimanda JE, 2015, 'Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias', Leukemia, 29, pp. 819 - 827, http://dx.doi.org/10.1038/leu.2014.299

Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB, 2015, 'Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia', Clinical Cancer Research, 21, pp. 1395 - 1405, http://dx.doi.org/10.1158/1078-0432.CCR-14-2300

Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ, 2015, 'Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program', Clinical Cancer Research, 21, pp. 819 - 832, http://dx.doi.org/10.1158/1078-0432.CCR-14-2572

Dolai S; Lock R, 2015, 'Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia', Blood, 125, pp. 1759 - 1767, http://dx.doi.org/10.1182/blood-2014-06-580480

Suryani S; Bracken LS; Harvey RC; Sia KCS; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB, 2015, 'Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia', Molecular Cancer Therapeutics, 14, pp. 364 - 374, http://dx.doi.org/10.1158/1535-7163.MCT-14-0647

Jing D; Bhadri VA; Beck D; Thoms JAI; Yakob NA; Wong JWH; Knezevic K; Pimanda JE; Lock RB, 2015, 'Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.', Blood, 125, pp. 273 - 283, http://dx.doi.org/10.1182/blood-2014-05-576470

Goossens S; Radaelli E; Blanchet O; Durinck K; Van Der Meulen J; Peirs S; Taghon T; Tremblay CS; Costa M; Ghahremani MF; De Medts J; Bartunkova S; Haigh K; Schwab C; Farla N; Pieters T; Matthijssens F; Van Roy N; Best JA; Deswarte K; Bogaert P; Carmichael C; Rickard A; Suryani S; Bracken LS; Alserihi R; Canté-Barrett K; Haenebalcke L; Clappier E; Rondou P; Slowicka K; Huylebroeck D; Goldrath AW; Janzen V; McCormack MP; Lock RB; Curtis DJ; Harrison C; Berx G; Speleman F; Meijerink JPP; Soulier J; Van Vlierberghe P; Haigh JJ, 2015, 'ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling', Nature Communications, 6, pp. 5794, http://dx.doi.org/10.1038/ncomms6794

Carol H; Fan MMY; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB, 2015, 'Efficacy of CPX-351, (cytarabine: DAunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 62, pp. 65 - 71, http://dx.doi.org/10.1002/pbc.25133

Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ, 2015, 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673', Pediatric Blood and Cancer, 62, pp. 91 - 98, http://dx.doi.org/10.1002/pbc.25201

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

Nowak D; Liem NLM; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP, 2015, 'Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance', Experimental Hematology, 43, pp. 32 - 43, http://dx.doi.org/10.1016/j.exphem.2014.09.007

Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB, 2015, 'p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.', Cell Cycle, 14, pp. 3602 - 3612, http://dx.doi.org/10.1080/15384101.2015.1100774

Toscan CE; Failes T; Arndt GM; Lock RB; Arndt G, 2014, 'High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers', Journal of Biomolecular Screening, 19, pp. 1391 - 1401, http://dx.doi.org/10.1177/1087057114546550

Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW, 2014, 'Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy', Cell Stem Cell, 15, pp. 775 - 790, http://dx.doi.org/10.1016/j.stem.2014.11.010

Suryani S; Carol H; Chonghaile TN; Frismantas V; Sarmah C; High L; Bornhauser B; Cowley MJ; Szymanska B; Evans K; Boehm I; Tonna E; Jones L; Manesh DM; Kurmasheva RT; Billups C; Kaplan W; Letai A; Bourquin J-P; Houghton PJ; Smith MA; Lock RB, 2014, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.', Clin Cancer Res, 20, pp. 4520 - 4531, http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial Testing (Stage 1) of the Notch Inhibitor PF-03084014, by the Pediatric Preclinical Testing Program (vol 61, pg 1493, 2014)', PEDIATRIC BLOOD & CANCER, 61, pp. 1716 - 1716, http://dx.doi.org/10.1002/pbc.25186

Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB, 2014, 'A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.', Blood Cancer J, 4, pp. e232, http://dx.doi.org/10.1038/bcj.2014.52

Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2014, 'Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1486 - 1489, http://dx.doi.org/10.1002/pbc.24989

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1493 - 1496, http://dx.doi.org/10.1002/pbc.25026

Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB, 2014, 'Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance', BMC Genomics, 15, http://dx.doi.org/10.1186/1471-2164-15-416

Jamieson SMF; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR, 2014, 'A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells', Biochemical Pharmacology, 88, pp. 36 - 45, http://dx.doi.org/10.1016/j.bcp.2013.12.019

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Gorlick R; Kolb EA; Maris JM; Reynolds CP; Kang MH; Carol H; Lock RB; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA; Keir ST, 2014, 'Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 61, pp. 158 - 164, http://dx.doi.org/10.1002/pbc.24616

Lock RB; Busfield S; Biondo M; Wong M; Ramshaw H; Lee E; Ghosh S; Braley H; Panousis C; Roberts A; He S; Thomas D; Fabri L; Vairo G; Lock REA, 2014, 'Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC', Leukemia, advance online publication, 9 May 2014, pp. 2213 - 2221, http://dx.doi.org/10.1038/leu.2014.128

Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KCS; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW, 2013, 'Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors', Cell Reports, 5, pp. 1047 - 1059, http://dx.doi.org/10.1016/j.celrep.2013.10.038

Carol H; Gorlick R; Kolb EA; Morton CL; Moradi Manesh D; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R, 2013, 'Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program', Pediatric Blood & Cancer, 61, pp. 245 - 252, http://dx.doi.org/10.1002/pbc.24724

Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 1325 - 1332, http://dx.doi.org/10.1002/pbc.24517

Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. E42 - E45, http://dx.doi.org/10.1002/pbc.24451

Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 791 - 798, http://dx.doi.org/10.1002/pbc.24301

Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2013, 'Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 633 - 641, http://dx.doi.org/10.1002/pbc.24235

Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB, 2013, 'The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia', Clinical Cancer Research, 19, pp. 1795 - 1805, http://dx.doi.org/10.1158/1078-0432.CCR-12-3613

Keir ST; Maris JM; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 783 - 790, http://dx.doi.org/10.1002/pbc.24368

Oram SH; Thoms J; Sive J; Calero-Nieto FJ; Kinston SJ; Schuette J; Knezevic K; Lock RB; Pimanda JE; Gottgens B, 2013, 'Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia', Leukemia, 27, pp. 1348 - 1357, http://dx.doi.org/10.1038/leu.2013.2

Piazza RG; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Gambacorti-passerini C, 2013, 'Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex', Neoplasia, 15, pp. 511 - 522, http://dx.doi.org/10.1593/neo.121784

Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Lock RB, 2013, 'Targeting acute myeloid leukemia by dual inhibition of P13K signalling and Cdk9-mediated Mcl-1 transcription', Blood, 122, pp. 738 - 748, http://dx.doi.org/10.1182/blood-2012-08-447441

Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Andreeff M; Konopleva M; Spong S; Thomas DA; Kantarjian H; Lock RB, 2013, 'Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth', Annals of Hematology, pp. 1 - 8, http://dx.doi.org/10.1007/s00277-013-1939-2

Shahbazi J; Lock RB; Liu T, 2013, 'Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis', Frontiers in Genetics, 13, pp. Art. No. 80, http://dx.doi.org/10.3389/fgene.2013.00080

Kan C-Y; Petti C; Bracken L; Maritz M; Xu N; O'Brien R; Yang C; Liu T; Yuan J; Lock RB; MacKenzie KL, 2013, 'Up-regulation of Survivin during Immortalization of Human Myofibroblasts Is Linked to Repression of Tumor Suppressor p16INK4a Protein and Confers Resistance to Oxidative Stress', Journal of Biological Chemistry, 288, pp. 12032 - 12041, http://dx.doi.org/10.1074/jbc.m112.447821

Wallington-Beddoe CT; Don AS; Hewson J; Qiao Q; Papa RA; Lock RB; Bradstock KF; Bendall LJ, 2012, 'Correction: Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia', PLOS ONE, 7, pp. 10.1371/annotation/d7342840-682b-4ee2-bb41-7b41aa5dedf7, http://dx.doi.org/10.1371/annotation/d7342840-682b-4ee2-bb41-7b41aa5dedf7

Lock RB; Don A; Qiao Q, 2012, 'Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia', PLoS ONE, 7, pp. e36429, http://dx.doi.org/10.1371/journal.pone.0036429

Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ, 2012, 'Erratum: Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 August; 59(2):246‐253', Pediatric Blood & Cancer, 59, pp. 772 - 772, http://dx.doi.org/10.1002/pbc.24291

Bhadri V; Trahair TN; Lock RB; bhadri , 2012, 'Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia', Journal of Paediatrics and Child Health, 48, pp. 634 - 640, http://dx.doi.org/10.1111/j.1440-1754.2011.02212.x

Markovic A; Mackenzie K; Lock RB, 2012, 'Induction of Vascular Endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway', Molecular Cancer Therapeutics, 11, pp. 183 - 193, http://dx.doi.org/10.1158/1535-7163.MCT-11-0503

Kolb EA; Gorlick R; Keir ST; Maris JM; Lock RB; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA, 2012, 'Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling', Pediatric Blood and Cancer, 58, pp. 815 - 818, http://dx.doi.org/10.1002/pbc.23290

Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Wozniak A; Smith MA, 2012, 'Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 185 - 188, http://dx.doi.org/10.1002/pbc.23154

Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 636 - 639, http://dx.doi.org/10.1002/pbc.23167

Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 749 - 752, http://dx.doi.org/10.1002/pbc.23364

Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock RB; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA, 2012, 'Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 1266 - 1274, http://dx.doi.org/10.1002/pbc.24073

Back to profile page